{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:21:51Z","timestamp":1763018511807,"version":"3.37.3"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-77-01"],"award-info":[{"award-number":["ANR-10-LABX-77-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Heterologous prime-boost strategies are of interest for HIV vaccine development. The order of prime-boost components could be important for the induction of T cell responses. In this phase I\/II multi-arm trial, three vaccine candidates were used as prime or boost: modified vaccinia Ankara (MVA) HIV-B (coding for Gag, Pol, Nef); HIV LIPO-5 (five lipopeptides from Gag, Pol, Nef); DNA GTU-MultiHIV B (coding for Rev, Nef, Tat, Gag, Env gp160 clade B). Healthy human volunteers (n = 92) were randomized to four groups: 1) MVA at weeks 0\/8 + LIPO-5 at weeks 20\/28 (M\/L); 2) LIPO-5 at weeks 0\/8 + MVA at weeks 20\/28 (L\/M); 3) DNA at weeks 0\/4\/12 + LIPO-5 at weeks 20\/28 (G\/L); 4) DNA at weeks 0\/4\/12 + MVA at weeks 20\/28 (G\/M). The frequency of IFN-\u03b3\u2013ELISPOT responders at week 30 was 33, 43, 0, and 74%, respectively. Only MVA-receiving groups were further analyzed (n = 62). Frequency of HIV-specific cytokine-positive (IFN-\u03b3, IL-2, or TNF-\u03b1) CD4+ T cells increased significantly from week 0 to week 30 (median change of 0.06, 0.11, and 0.10% for M\/L, L\/M, and G\/M, respectively), mainly after MVA vaccinations, and was sustained until week 52. HIV-specific CD8+ T cell responses increased significantly at week 30 in M\/L and G\/M (median change of 0.02 and 0.05%). Significant whole-blood gene expression changes were observed 2 wk after the first MVA injection, regardless of its use as prime or boost. An MVA gene signature was identified, including 86 genes mainly related to cell cycle pathways. Three prime-boost strategies led to CD4+ and CD8+ T cell responses and to a whole-blood gene expression signature primarily due to their MVA HIV-B component.<\/jats:p>","DOI":"10.4049\/jimmunol.2101076","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T16:23:59Z","timestamp":1657815839000},"page":"2663-2674","source":"Crossref","is-referenced-by-count":10,"title":["T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I\/II ANRS VRI01 Trial"],"prefix":"10.1093","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7682-2225","authenticated-orcid":false,"given":"Laura","family":"Richert","sequence":"first","affiliation":[{"name":"University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR1219 , Bordeaux,","place":["France"]},{"name":"Inria SISTM Team , Talence,","place":["France"]},{"name":"CHU de Bordeaux, Service d\u2019Information M\u00e9dicale , Bordeaux,","place":["France"]},{"name":"Vaccine Research Institute , Cr\u00e9teil,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Daniel","family":"Leli\u00e8vre","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil,","place":["France"]},{"name":"INSERM U955, Universit\u00e9 Paris-Est Cr\u00e9teil , Cr\u00e9teil,","place":["France"]},{"name":"Groupe Henri-Mondor Albert-Chenevier, AP-HP , Cr\u00e9teil,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-0225","authenticated-orcid":false,"given":"Christine","family":"Lacabaratz","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil,","place":["France"]},{"name":"INSERM U955, Universit\u00e9 Paris-Est Cr\u00e9teil , Cr\u00e9teil,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucile","family":"Hardel","sequence":"additional","affiliation":[{"name":"University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR1219 , Bordeaux,","place":["France"]},{"name":"Vaccine Research Institute , Cr\u00e9teil,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4972-3547","authenticated-orcid":false,"given":"Hakim","family":"Hocini","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil,","place":["France"]},{"name":"INSERM U955, Universit\u00e9 Paris-Est Cr\u00e9teil , Cr\u00e9teil,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-3137","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Wiedemann","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil,","place":["France"]},{"name":"INSERM U955, Universit\u00e9 Paris-Est Cr\u00e9teil , Cr\u00e9teil,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Lucht","sequence":"additional","affiliation":[{"name":"CHU de Saint Etienne , Saint-Priest-en-Jarez,","place":["France"]},{"name":"Universit\u00e9 Jean Monnet and Universit\u00e9 de Lyon , Saint-Etienne,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5676-5411","authenticated-orcid":false,"given":"Isabelle","family":"Poizot-Martin","sequence":"additional","affiliation":[{"name":"Aix-Marseille Universit\u00e9, APHM, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Sant\u00e9 & Traitement de l\u2019Information M\u00e9dicale, ISSPAM, APHM Sainte-Marguerite, Service d\u2019Immuno-H\u00e9matologie Clinique , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Bauduin","sequence":"additional","affiliation":[{"name":"University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR1219 , Bordeaux,","place":["France"]},{"name":"Vaccine Research Institute , Cr\u00e9teil,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9642-0584","authenticated-orcid":false,"given":"Alpha","family":"Diallo","sequence":"additional","affiliation":[{"name":"INSERM-ANRS , Paris,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6123-0051","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Rieux","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil,","place":["France"]},{"name":"INSERM-ANRS , Paris,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1647-5580","authenticated-orcid":false,"given":"Elodie","family":"Rouch","sequence":"additional","affiliation":[{"name":"University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR1219 , Bordeaux,","place":["France"]},{"name":"Vaccine Research Institute , Cr\u00e9teil,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Surenaud","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil,","place":["France"]},{"name":"INSERM U955, Universit\u00e9 Paris-Est Cr\u00e9teil , Cr\u00e9teil,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6408-0201","authenticated-orcid":false,"given":"C\u00e9cile","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil,","place":["France"]},{"name":"INSERM U955, Universit\u00e9 Paris-Est Cr\u00e9teil , Cr\u00e9teil,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emile","family":"Foucat","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil,","place":["France"]},{"name":"INSERM U955, Universit\u00e9 Paris-Est Cr\u00e9teil , Cr\u00e9teil,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1686-3823","authenticated-orcid":false,"given":"Pascaline","family":"Tisserand","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil,","place":["France"]},{"name":"INSERM U955, Universit\u00e9 Paris-Est Cr\u00e9teil , Cr\u00e9teil,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Guillaumat","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil,","place":["France"]},{"name":"INSERM U955, Universit\u00e9 Paris-Est Cr\u00e9teil , Cr\u00e9teil,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lany","family":"Durand","sequence":"additional","affiliation":[{"name":"University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR1219 , Bordeaux,","place":["France"]},{"name":"Inria SISTM Team , Talence,","place":["France"]},{"name":"Vaccine Research Institute , Cr\u00e9teil,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0646-452X","authenticated-orcid":false,"given":"Boris","family":"Hejblum","sequence":"additional","affiliation":[{"name":"University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR1219 , Bordeaux,","place":["France"]},{"name":"Inria SISTM Team , Talence,","place":["France"]},{"name":"Vaccine Research Institute , Cr\u00e9teil,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odile","family":"Launay","sequence":"additional","affiliation":[{"name":"CIC 1417 F-CRIN I-REIVAC, INSERM, H\u00f4pital Cochin, AP-HP , Paris,","place":["France"]},{"name":"Universit\u00e9 Paris Descartes , Paris,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5235-3962","authenticated-orcid":false,"given":"Rodolphe","family":"Thi\u00e9baut","sequence":"additional","affiliation":[{"name":"University of Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR1219 , Bordeaux,","place":["France"]},{"name":"Inria SISTM Team , Talence,","place":["France"]},{"name":"CHU de Bordeaux, Service d\u2019Information M\u00e9dicale , Bordeaux,","place":["France"]},{"name":"Vaccine Research Institute , Cr\u00e9teil,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5549-6256","authenticated-orcid":false,"given":"Yves","family":"L\u00e9vy","sequence":"additional","affiliation":[{"name":"Vaccine Research Institute , Cr\u00e9teil,","place":["France"]},{"name":"INSERM U955, Universit\u00e9 Paris-Est Cr\u00e9teil , Cr\u00e9teil,","place":["France"]},{"name":"Groupe Henri-Mondor Albert-Chenevier, AP-HP , Cr\u00e9teil,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"2025021009082964300_r1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14760584.2020.1718497","article-title":"Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges","volume":"19","author":"Pitisuttithum","year":"2020","journal-title":"Expert Rev. Vaccines"},{"key":"2025021009082964300_r2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S2055-6640(20)30695-6","article-title":"HIV-1 prophylactic vaccines: state of the art","volume":"2","author":"Leli\u00e8vre","year":"2016","journal-title":"J. Virus Erad."},{"key":"2025021009082964300_r3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41577-018-0103-6","article-title":"Advancing an HIV vaccine; advancing vaccinology","volume":"19","author":"Burton","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"2025021009082964300_r4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/COH.0000000000000313","article-title":"Designing optimal HIV-vaccine T-cell responses","volume":"11","author":"Streeck","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"key":"2025021009082964300_r5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/COH.0000000000000324","article-title":"Therapeutic vaccines and immunological intervention in HIV infection: a paradigm change","volume":"11","author":"Pantaleo","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"key":"2025021009082964300_r6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/COH.0000000000000491","article-title":"Therapeutic vaccination for HIV: hopes and challenges","volume":"13","author":"Stephenson","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"2025021009082964300_r7","doi-asserted-by":"crossref","first-page":"e02165-20","DOI":"10.1128\/JVI.02165-20","article-title":"A randomized placebo-controlled efficacy study of a prime boost therapeutic vaccination strategy in HIV-1-infected individuals: VRI02 ANRS 149 LIGHT phase II trial","volume":"95","author":"L\u00e9vy","year":"2021","journal-title":"J. Virol."},{"key":"2025021009082964300_r8","doi-asserted-by":"crossref","first-page":"20497","DOI":"10.7448\/IAS.18.1.20497","article-title":"Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions","volume":"18","author":"Graziani","year":"2015","journal-title":"J. Int. AIDS Soc."},{"key":"2025021009082964300_r9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1126\/science.1255512","article-title":"Immunologic strategies for HIV-1 remission and eradication","volume":"345","author":"Barouch","year":"2014","journal-title":"Science"},{"author":"Treatment Action Group","key":"2025021009082964300_r10","article-title":"Research toward a cure trials"},{"key":"2025021009082964300_r11","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"2025021009082964300_r12","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2031499","article-title":"Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults","volume":"384","author":"Gray","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2025021009082964300_r13","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/14760584.2019.1640117","article-title":"Novel prime-boost vaccine strategies against HIV-1","volume":"18","author":"Excler","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"2025021009082964300_r14","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1586\/14760584.2016.1158108","article-title":"New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design","volume":"15","author":"Musich","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"2025021009082964300_r15","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"2025021009082964300_r16","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nbt.3187","article-title":"COMPASS identifies T-cell subsets correlated with clinical outcomes","volume":"33","author":"Lin","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"2025021009082964300_r17","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1128\/JVI.02329-09","article-title":"Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect","volume":"84","author":"Brandler","year":"2010","journal-title":"J. Virol."},{"key":"2025021009082964300_r18","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1097\/QAD.0b013e32835f5b60","article-title":"Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers","volume":"27","author":"Richert","year":"2013","journal-title":"AIDS"},{"key":"2025021009082964300_r19","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/14760584.2017.1374182","article-title":"Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccines","volume":"16","author":"Surenaud","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"2025021009082964300_r20","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.3389\/fimmu.2019.02911","article-title":"The safety and immunogenicity of GTU\u00aeMultiHIV DNA vaccine delivered by transcutaneous and intramuscular injection with or without electroporation in HIV-1 positive subjects on suppressive ART","volume":"10","author":"Haidari","year":"2019","journal-title":"Front. Immunol."},{"key":"2025021009082964300_r21","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1016\/j.vaccine.2012.04.007","article-title":"Indicators of therapeutic effect in FIT-06, a phase II trial of a DNA vaccine, GTU\u00ae-Multi-HIVB, in untreated HIV-1 infected subjects","volume":"30","author":"Vardas","year":"2012","journal-title":"Vaccine"},{"key":"2025021009082964300_r22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1745-6215-15-68","article-title":"Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I\/II trial design","volume":"15","author":"Richert","year":"2014","journal-title":"Trials"},{"key":"2025021009082964300_r23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs","volume":"20","author":"A\u2019Hern","year":"2001","journal-title":"Stat. Med."},{"key":"2025021009082964300_r24","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1214\/aos\/1013699998","article-title":"The control of the false discovery rate in multiple testing under dependency","volume":"29","author":"Benjamini","year":"2001","journal-title":"Ann. Stat."},{"key":"2025021009082964300_r25","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/bioinformatics\/btp040","article-title":"Statistical methods of background correction for Illumina BeadArray data","volume":"25","author":"Xie","year":"2009","journal-title":"Bioinformatics"},{"key":"2025021009082964300_r26","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1093\/nar\/gkq871","article-title":"Optimizing the noise versus bias trade-off for Illumina whole genome expression BeadChips","volume":"38","author":"Shi","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"2025021009082964300_r27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","article-title":"Adjusting batch effects in microarray expression data using empirical Bayes methods","volume":"8","author":"Johnson","year":"2007","journal-title":"Biostatistics"},{"key":"2025021009082964300_r28","doi-asserted-by":"crossref","first-page":"lqaa093","DOI":"10.1093\/nargab\/lqaa093","article-title":"dearseq: a variance component score test for RNA-seq differential analysis that effectively controls the false discovery rate","volume":"2","author":"Gauthier","year":"2020","journal-title":"NAR Genom. Bioinform."},{"key":"2025021009082964300_r29","doi-asserted-by":"crossref","first-page":"e1004310","DOI":"10.1371\/journal.pcbi.1004310","article-title":"Time-course gene set analysis for longitudinal gene expression data. [Published erratum appears in 2015 PLoS Comput. Biol. 11: e1004446]","volume":"11","author":"Hejblum","year":"2015","journal-title":"PLoS Comput. Biol."},{"key":"2025021009082964300_r30","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.immuni.2008.05.012","article-title":"A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus","volume":"29","author":"Chaussabel","year":"2008","journal-title":"Immunity"},{"key":"2025021009082964300_r31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/ni.2789","article-title":"Molecular signatures of antibody responses derived from a systems biology study of five human vaccines","volume":"15","author":"Li","year":"2014","journal-title":"Nat. Immunol."},{"key":"2025021009082964300_r32","doi-asserted-by":"crossref","first-page":"eabd9720","DOI":"10.1126\/scisignal.abd9720","article-title":"Single-cell analysis reveals divergent responses of human dendritic cells to the MVA vaccine","volume":"14","author":"D\u00f6ring","year":"2021","journal-title":"Sci. Signal."},{"key":"2025021009082964300_r33","doi-asserted-by":"crossref","first-page":"e1008522","DOI":"10.1371\/journal.ppat.1008522","article-title":"Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03\/ANRS VAC20 phase I\/II trial","volume":"16","author":"L\u00e9vy","year":"2020","journal-title":"PLoS Pathog."},{"key":"2025021009082964300_r34","doi-asserted-by":"crossref","first-page":"e0179597","DOI":"10.1371\/journal.pone.0179597","article-title":"Immunogenicity of a novel clade B HIV-1 vaccine combination: results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults","volume":"12","author":"Buchbinder","year":"2017","journal-title":"PLoS One"},{"key":"2025021009082964300_r35","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3018(19)30262-0","article-title":"Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial","volume":"6","author":"Pantaleo","year":"2019","journal-title":"Lancet HIV"},{"key":"2025021009082964300_r36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/cid\/ciz1239","article-title":"Phase 1 human immunodeficiency virus (HIV) vaccine trial to evaluate the safety and immunogenicity of HIV subtype C DNA and MF59-adjuvanted subtype C envelope protein","volume":"72","author":"Hosseinipour","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"2025021009082964300_r37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-981-13-0484-2_2","article-title":"HIV T-cell vaccines","volume":"1075","author":"Mothe","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"2025021009082964300_r38","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nm.f.1759","article-title":"Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans","volume":"14","author":"Watkins","year":"2008","journal-title":"Nat. Med."},{"key":"2025021009082964300_r39","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"Hammer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2025021009082964300_r40","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"2025021009082964300_r41","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet"},{"key":"2025021009082964300_r42","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/infdis\/jix086","article-title":"Higher T-cell responses induced by DNA\/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial","volume":"215","author":"Janes","year":"2017","journal-title":"J. Infect. Dis."},{"key":"2025021009082964300_r43","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature10003","article-title":"Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine","volume":"473","author":"Hansen","year":"2011","journal-title":"Nature"},{"key":"2025021009082964300_r44","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature12519","article-title":"Immune clearance of highly pathogenic SIV infection. [Published erratum appears in 2014 Nature 514: 654.]","volume":"502","author":"Hansen","year":"2013","journal-title":"Nature"},{"key":"2025021009082964300_r45","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"key":"2025021009082964300_r46","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1002\/eji.201344433","article-title":"Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load","volume":"44","author":"L\u00e9vy","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"2025021009082964300_r47","first-page":"279","article-title":"Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients","volume":"19","author":"L\u00e9vy","year":"2005","journal-title":"AIDS"},{"key":"2025021009082964300_r48","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.aids.0000206504.09159.d3","article-title":"Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals","volume":"20","author":"L\u00e9vy","year":"2006","journal-title":"AIDS"},{"key":"2025021009082964300_r49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/infdis\/jiq077","article-title":"A therapeutic dendritic cell-based vaccine for HIV-1 infection","volume":"203","author":"Garc\u00eda","year":"2011","journal-title":"J. Infect. Dis."},{"key":"2025021009082964300_r50","doi-asserted-by":"crossref","first-page":"166ra2","DOI":"10.1126\/scitranslmed.3004682","article-title":"A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication","volume":"5","author":"Garc\u00eda","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"2025021009082964300_r51","doi-asserted-by":"crossref","first-page":"eaaw1673","DOI":"10.1126\/scitranslmed.aaw1673","article-title":"Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial","volume":"11","author":"Kallas","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"2025021009082964300_r52","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/infdis\/jit322","article-title":"Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection","volume":"208","author":"Janes","year":"2013","journal-title":"J. Infect. Dis."},{"key":"2025021009082964300_r53","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1080\/21645515.2015.1016671","article-title":"Dose-dependent inhibition of Gag cellular immunity by Env in SIV\/HIV DNA vaccinated macaques","volume":"11","author":"Valentin","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"2025021009082964300_r54","doi-asserted-by":"crossref","first-page":"eaaw4236","DOI":"10.1126\/scitranslmed.aaw4236","article-title":"A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials","volume":"11","author":"Ehrenberg","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"2025021009082964300_r55","doi-asserted-by":"crossref","first-page":"13031","DOI":"10.1038\/s41598-020-69007-w","article-title":"Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature","volume":"10","author":"Palli","year":"2020","journal-title":"Sci. Rep."},{"key":"2025021009082964300_r56","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/1471-2334-14-314","article-title":"Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response","volume":"14","author":"Matsumiya","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"2025021009082964300_r57","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.celrep.2017.08.023","article-title":"Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine rVSV-ZEBOV","volume":"20","author":"Rechtien","year":"2017","journal-title":"Cell Rep."},{"key":"2025021009082964300_r58","doi-asserted-by":"crossref","first-page":"e1009363","DOI":"10.1371\/journal.ppat.1009363","article-title":"Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk","volume":"17","author":"Andersen-Nissen","year":"2021","journal-title":"PLoS Pathog."},{"key":"2025021009082964300_r59","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3389\/fimmu.2019.00874","article-title":"Gene expression signatures associated with immune and virological responses to therapeutic vaccination with dendritic cells in HIV-infected individuals","volume":"10","author":"Thi\u00e9baut","year":"2019","journal-title":"Front. Immunol."},{"key":"2025021009082964300_r60","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.coviro.2016.01.007","article-title":"Selection of HIV vaccine candidates for concurrent testing in an efficacy trial","volume":"17","author":"Huang","year":"2016","journal-title":"Curr. Opin. Virol."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/208\/12\/2663\/61466002\/ji2101076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/208\/12\/2663\/61466002\/ji2101076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T09:08:52Z","timestamp":1739178532000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/208\/12\/2663\/7927290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,6,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.2101076","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"type":"print","value":"0022-1767"},{"type":"electronic","value":"1550-6606"}],"subject":[],"published-other":{"date-parts":[[2022,6]]},"published":{"date-parts":[[2022,6]]}}}